Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: A report from the children's cancer group

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 3956-3962

  Frangoul, Haydar ^a,f   Ames, Matthew M ^b   Mosher, Revonda B ^c   Reid, Joel M ^b   Krailo, Mark D ^f   Seibel, Nita L ^c   Shaw, Dennis W W ^a   Steinherz, Peter G ^d   Whitlock, James A ^e   Holcenberg, John S ^a  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TOLERANCE; GASTROINTESTINAL TOXICITY; HUMAN; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM RECURRENCE, LOCAL; TOPOTECAN;

EID: 0033391318     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., and Lim, G. A. Plant antitumor agents: the isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from camptotheca acumminata. J. Am. Chem. Soc., 88: 3888-3890, 1966.
2. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep., 54: 461-470, 1970.
3. Moertel, C. G., Schutt, A. J., Reitemeier, R. J., and Hahn, R. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56: 95-101, 1972.
4. Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H., and Selawry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 56: 515-521, 1972.
5. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., and Hertzberg, R. P. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
6. Creemers, G. J., Lund, B., and Verweij, J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 20: 73-96, 1994.
7. Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chern., 260: 14873-14878, 1985.
8. Hsiang, Y. H., and Liu, L. F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722-1726, 1988.
9. Friedman, H. S., Houghton, P. J., Schold, S. C., Keir, S., and Bigner, D. D. Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol., 34: 171-174, 1994.
10. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
11. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Jr., Lutz, L., Friedman, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
12. Wall, J. G., Burris, H. A. d., Von Hoff, D. D., Rodriguez, G., Kneuper-Hall, R., Shaffer, D., O'Rourke, T., Brown, T., Weiss, G., Clark, G., McVea, S., Brown, J., Johnson, R., Friedman, C., Smith, B., Mann, W. S., and Kuhn, J. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs, 3: 337-345, 1992.
13. Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., Kaufmann, S. H., and Donehower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647-656, 1992.
14. Haas, N. B., LaCreta, F. P., Walczak, J., Hudes, G. R., Brennan, J. M., Ozols, R. F., and O'Dwyer, P. J. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res., 54: 1220-1226, 1994.
15. Burris, H. A., Awada, A., Kuhn, J. G., Eckardt, J. R., Cobb, P. W., Rinaldi, D. A., Fields, S., Smith, L., and Von Hoff, D. D. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs, 5: 394-402, 1994.
16. ten Bokkel Huinink, W., Carmichael, J., Armstrong, D., Gordon, A., and Malfetano, J. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin. Oncol., 24: S5-S19, 1997.
17. Blaney, S. M., Needle, M., Gillespie, A., Sato, J. K., Reaman, G. H., Berg, S. L., Adamson, P. C., Krailo, M. D., Bleyer, W. A., Poplack, D. G., and Balis, F. M. Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group study. Clin. Cancer Res., 4: 357-360, 1998.
18. Bowman, L. C., Stewart, C. F., Zamboni, W. C., Crom, W. R., Luo, X., Heideman, R., Houghton, P. J., Meyer, W. H., and Pratt, C. B. Toxicity and pharmacodynamics of oral topotecan in pediatric patients with relapsed solid tumors. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 15: A1453, 1996.
19. Gerrits, C., Schellens, J., Burris, H., Planting, A., van der Burg, M., van Beurden, W., Loos, W., Hudson, I., Fields, S., Von Hoff, D., and Verweij, J. Prolonged exposure to oral topotecan (TPT), correlates between pharmacokinetics and toxicity. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: A244, 1997.
20. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Raphael, B., Vinci, R. Z., and Blum, R. H. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol., 12: 553-559, 1994.
21. Creemers, G. J., Gerrits, C. J., Schellens, J. H., Planting, A. S., van der Burg, M. E., van Beurden, V. M., de Boer Dennert, M., Harteveld, M., Loos, W., Hudson, I., Stoter, G., and Verweij, J. Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J. Clin. Oncol., 14: 2540-2545, 1996.
22. Pratt, C. B., Stewart, C., Santana, V. M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J. F., Heideman, R., Sandlund, J. T., Avery, L., and Meyer, W. H. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 12: 539-543, 1994.
23. Blaney, S. M., Balis, F. M., Cole, D. E., Craig, C., Reid, J. M., Ames, M. M., Krailo, M., Reaman, G., Hammond, D., and Poplack, D. G. Pediatric Phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res., 53: 1032-1036, 1993.
24. Herben, V. M., ten Bokkel Huinink, W. W., Schot, M. E., Hudson, I., and Beijnen, J. H. Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a Phase II study in patients with small cell lung cancer. Anticancer Drugs, 9: 411-418, 1998.
25. Furman, W. L., Baker, S. D., Pratt, C. B., Rivera, G. K., Evans, W. E., and Stewart, C. F. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J. Clin. Oncol., 14: 1504-1511, 1996.
26. Kantarjian, H. M., Beran, M., Ellis, A., Zwelling, L., O'Brien, S., Cazenave, L., Koller, C., Rios, M. B., Plunkett, W., Keating, M. J., and Estey, E. H. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood, 81: 1146-1151, 1993.
27. Rowinsky, E. K., Adjei, A., Donehower, R. C., Gore, S. D., Jones, R. J., Burke, P. J., Cheng, Y. C., Grochow, L. B., and Kaufmann, S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol., 12: 2193-2203, 1994.
28. Hochster, H., Liebes, L., Speyer, J., Sorich, J., Taubes, B., Oratz, R., Wernz, J., Chachoua, A., Blum, R. H., and Zeleniuch-Jacquotte, A. Effect of prolonged topotecan infusion on topoisomerase I levels: a Phase I and pharmacodynamic study. Clin. Cancer Res., 3: 1245-1252, 1997.
29. Beijnen, J. H., Smith, B. R., Keijer, W. J., Van Gijn, R., ten Bokkel Humink, W. W., Vlasveld, L. T., Rodenhuis, S., and Underberg, W. J. High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-1 (NSC 609699) in plasma. J. Pharm. Biomed. Anal., 8: 789-794, 1990.
30. van Warmerdam, L. J., ten Bokkel Huinink, W. W., Rodenhuis, S., Koier, I., Davies, B. E., Rosing, H., Maes, R. A., and Beijnen, J. H. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. J. Clin. Oncol., 13: 1768-1776, 1995.
31. Stewart, C. F., Baker, S. D., Heideman, R. L., Jones, D., Crom, W. R., and Pratt, C. B. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. J. Clin. Oncol., 12: 1946-1954, 1994.
32. Grochow, L. B., Rowinsky, E. K., Johnson, R., Ludeman, S., Kaufman, S. H., McCabe, F. L., Smith, B. R., Hurowitz, L., DeLisa, A., Donehower, R. C., and Noe, D. A. Pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab. Dispos., 20: 706-713, 1992.
33. Herben, V. M., ten Bokkel Huinink, W. W., and Beijnen, J. H. Clinical pharmacokinetics of topotecan. Clin. Pharmacokinet., 31: 85-102, 1996.
34. Carlson, L., Ho, P., Smith, M., Reisch, J., and Weitman, S. Pediatric Phase I drug tolerance: a review and comparison of recent adult and Phase I trials. J. Pediatr. Hematol. Oncol., 18: 250-256, 1996.
35. Smith, M., Bernstein, M., Bleyer, W. A., Borsi, J. D., Ho, P., Lewis, I. J., Pearson, A., Pein, F., Pratt, C., Reaman, G., Riccardi, R., Seibel, N., Trueworthy, R., Ungerleider, R., Vassal, G., and Vietti, T. Conduct of Phase I trials in children with cancer. J. Clin. Oncol., 16: 966-978, 1998.
36. Pommier, Y., Leteurtre, F., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542, 1994.
37. Houghton, P., Stewart, C., Zamboni, W., Thompson, J., Luo, X., and Houghton, J. Schedule-dependent efficacy of camptothecins in models of human cancer. Ann. NY Acad. Sci., 803: 188-201, 1996.
38. Zamboni, W., Stewart, C., Thompson, J., Santana, V., Cheshire, P., Richmond, L., Luo, X., Poquette, C., Houghton, J., and Houghton, P. Relationship between topotecan systemic exposure and tumor response. J. Natl. Cancer Inst., 90: 505-511, 1998.
39. Danks, M., Garrett, K., Marion, R., and Whipple, D. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res., 50: 1664-1673, 1996.
40. Pawlik, C., Houghton, P., Stewart, C., Cheshire, P., Richmond, L., and Danks, M. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays. Clin. Cancer Res., 4: 1995-2002, 1998.
41. Wadkins, R., Danks, M., Horowitz, L., and Baker, S. Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy. Exp. Cell Res., 241: 332-339, 1998.
42. Hoskins, P., Eisenhauer, E., Beare, S., Roy, M., Drouin, P., Stuart, G., Bryson, P., Grimshaw, R., Capstick, V., and Zee, B. Randomized Phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol., 16: 2233-2237, 1998.